Evidence map›Paper›PMID 33063175›Full record

ReviewCurrent genetics2021

Redundant targeting of Isr1 by two CDKs in mitotic cells.

Emma B Alme, David P Toczyski

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emma B AlmeDepartment of Biochemistry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
David P ToczyskiDepartment of Biochemistry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. dpt4darwin@gmail.com.ORCID http://orcid.org/0000-0001-5924-0365
University of California, San Francisco · US

Funding

GENETICS OF EUCARYOTIC AND PROCARYOTIC ORGANISMST32GM007810 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ASHRAFI, KAVEH, NARLIKAR, GEETA J · 1985 to 2020
$15.1M
Regulation by post-translation modifications in response to stressR35GM118104 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TOCZYSKI, DAVID PAUL · 2016 to 2025
$7.2M
NIGMS NIH HHS R35 GM118104NIGMS NIH HHS T32 GM007810NIH HHS R35GM118104
6 · The paper itself

Abstract

Protein phosphorylation is an essential regulatory mechanism that controls most cellular processes, integrating a variety of environmental signals to drive cellular growth. Isr1 is a negative regulator of the hexosamine biosynthesis pathway (HBP), which produces UDP-GlcNAc, an essential carbohydrate that is the building block of N-glycosylation, GPI anchors and chitin. Isr1 was recently shown to be regulated by phosphorylation by the nutrient-responsive CDK kinase Pho85, allowing it to be targeted for degradation by the SCF

Indexed as

Biosynthetic PathwaysCDC2 Protein KinaseCell CycleCell Cycle ProteinsCyclin-Dependent KinasesF-Box ProteinsGlucosamineGlycosylationHexosaminesMitosisPhosphorylationSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSignal TransductionUbiquitin-Protein LigasesCDC2 Protein KinaseCDC4 protein, S cerevisiaeCell Cycle ProteinsCyclin-Dependent KinasesF-Box ProteinsGlucosamineHexosaminesPHO85 protein, S cerevisiaeSaccharomyces cerevisiae ProteinsUbiquitin-Protein LigasesUDP-glucosamineCDC4CDK1GFA1ISR1PHO85

Identifiers

PMID33063175
PMCPMC7886961
OpenAlexW3093035338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.